vs
Side-by-side financial comparison of Eightco Holdings Inc. (ORBS) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $10.2M, roughly 1.2× Eightco Holdings Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -2281.6%, a 2532.3% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -49.9%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 13.1%).
ORBS vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.2M | $12.6M |
| Net Profit | $-232.5M | $31.5M |
| Gross Margin | -13.0% | — |
| Operating Margin | -475.0% | — |
| Net Margin | -2281.6% | 250.7% |
| Revenue YoY | -49.9% | 24080.8% |
| Net Profit YoY | -9183.3% | 250.9% |
| EPS (diluted) | $-2.34 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.2M | $12.6M | ||
| Q3 25 | $5.3M | $0 | ||
| Q2 25 | $7.6M | $0 | ||
| Q1 25 | $9.9M | $12.0K | ||
| Q4 24 | $20.3M | $52.0K | ||
| Q3 24 | $6.1M | $65.0K | ||
| Q2 24 | $5.3M | $114.0K | ||
| Q1 24 | $8.0M | $140.0K |
| Q4 25 | $-232.5M | $31.5M | ||
| Q3 25 | $-25.8M | $-7.4M | ||
| Q2 25 | $-1.2M | $-1.7M | ||
| Q1 25 | $-2.5M | $-13.9M | ||
| Q4 24 | $-2.5M | — | ||
| Q3 24 | $-3.2M | $-17.1M | ||
| Q2 24 | $4.4M | $-17.9M | ||
| Q1 24 | $1.9M | $-12.7M |
| Q4 25 | -13.0% | — | ||
| Q3 25 | -3.7% | — | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 8.2% | — | ||
| Q4 24 | 8.2% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 25.1% | — | ||
| Q1 24 | 17.5% | — |
| Q4 25 | -475.0% | — | ||
| Q3 25 | -116.9% | — | ||
| Q2 25 | -15.9% | — | ||
| Q1 25 | -14.3% | -122758.3% | ||
| Q4 24 | -11.9% | — | ||
| Q3 24 | -29.1% | -28604.6% | ||
| Q2 24 | -16.4% | -16720.2% | ||
| Q1 24 | -39.6% | -9987.1% |
| Q4 25 | -2281.6% | 250.7% | ||
| Q3 25 | -487.6% | — | ||
| Q2 25 | -15.4% | — | ||
| Q1 25 | -25.7% | -115550.0% | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -52.5% | -26380.0% | ||
| Q2 24 | 84.2% | -15668.4% | ||
| Q1 24 | 24.4% | -9049.3% |
| Q4 25 | $-2.34 | $0.56 | ||
| Q3 25 | $-0.58 | $-0.13 | ||
| Q2 25 | $-0.38 | $-0.03 | ||
| Q1 25 | $-0.84 | $-0.25 | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $-1.77 | $-0.32 | ||
| Q2 24 | $2.15 | $-0.33 | ||
| Q1 24 | $1.42 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.5M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $232.6M | $59.0M |
| Total Assets | $250.2M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.5M | $40.3M | ||
| Q3 25 | $23.7M | $48.6M | ||
| Q2 25 | $696.3K | $31.2M | ||
| Q1 25 | $434.4K | $48.9M | ||
| Q4 24 | $239.2K | $52.9M | ||
| Q3 24 | $2.4M | $76.3M | ||
| Q2 24 | $363.1K | $63.5M | ||
| Q1 24 | $808.8K | $82.3M |
| Q4 25 | $232.6M | $59.0M | ||
| Q3 25 | $339.2M | $26.5M | ||
| Q2 25 | $8.9M | $32.8M | ||
| Q1 25 | $9.7M | $33.8M | ||
| Q4 24 | $11.9M | $46.1M | ||
| Q3 24 | $13.0M | $65.5M | ||
| Q2 24 | $13.8M | $80.5M | ||
| Q1 24 | $3.9M | $96.2M |
| Q4 25 | $250.2M | $68.9M | ||
| Q3 25 | $355.5M | $54.2M | ||
| Q2 25 | $48.7M | $62.1M | ||
| Q1 25 | $47.6M | $77.7M | ||
| Q4 24 | $50.8M | $110.5M | ||
| Q3 24 | $49.2M | $135.2M | ||
| Q2 24 | $48.4M | $149.9M | ||
| Q1 24 | $50.2M | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.0M | $-8.4M |
| Free Cash FlowOCF − Capex | $-11.0M | — |
| FCF MarginFCF / Revenue | -107.7% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.0M | $-8.4M | ||
| Q3 25 | $-1.6M | $17.4M | ||
| Q2 25 | $-659.2K | $-17.7M | ||
| Q1 25 | $999.8K | $-4.0M | ||
| Q4 24 | $-6.6M | $-23.4M | ||
| Q3 24 | $77.7K | $12.8M | ||
| Q2 24 | $-440.3K | $-18.7M | ||
| Q1 24 | $-723.3K | $5.9M |
| Q4 25 | $-11.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-661.3K | — | ||
| Q1 25 | $999.7K | — | ||
| Q4 24 | $-6.6M | — | ||
| Q3 24 | $73.0K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -107.7% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -8.7% | — | ||
| Q1 25 | 10.1% | — | ||
| Q4 24 | -32.7% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.10× | — | ||
| Q1 24 | -0.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
